S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind

InVivo Therapeutics Stock Price, News & Analysis (NASDAQ:NVIV)

$0.71
-0.02 (-2.74%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.65
▼
$0.74
50-Day Range
$0.60
▼
$1.19
52-Week Range
$0.60
▼
$2.80
Volume
27,885 shs
Average Volume
48,191 shs
Market Capitalization
$2.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

NVIV stock logo

About InVivo Therapeutics Stock (NASDAQ:NVIV)

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

NVIV Stock Price History

NVIV Stock News Headlines

December 2, 2023 | americanbankingnews.com
InVivo Therapeutics (NASDAQ:NVIV) Research Coverage Started at StockNews.com
November 10, 2023 | morningstar.com
InVivo Therapeutics Holdings Corp NVIV
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
June 22, 2023 | marketwatch.com
Spinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030
May 1, 2023 | benzinga.com
Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy
March 17, 2023 | finance.yahoo.com
Why InVivo Therapeutics Shares Are Plunging Today
March 10, 2023 | msn.com
InVivo seeks longer-term control in Casino-Teract retail tie-up
March 10, 2023 | msn.com
Why Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
March 10, 2023 | msn.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%
March 9, 2023 | msn.com
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 9, 2023 | markets.businessinsider.com
InVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpoint
March 9, 2023 | msn.com
InVivo to evaluate strategic options as trial for spinal injury device fails
March 9, 2023 | marketwatch.com
InVivo Therapeutics Shares Hit 52-Week Low After Study Misses Primary Endpoint
March 9, 2023 | marketwatch.com
InVivo Therapeutics Study for Neuro-Spinal Scaffold Misses Primary Endpoint
March 9, 2023 | finance.yahoo.com
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
January 11, 2023 | benzinga.com
InVivo Therapeutics Hldg Stock (NASDAQ:NVIV), Quotes and News Summary
October 11, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
October 10, 2022 | marketwatch.com
InVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday Low
October 7, 2022 | seekingalpha.com
InVivo Therapeutics dips 24% on $9M direct and private placement offerings
October 7, 2022 | marketwatch.com
InVivo Therapeutics Stock Drops on $9 Million Offering
October 7, 2022 | investorplace.com
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
October 7, 2022 | finance.yahoo.com
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
September 9, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
August 28, 2022 | uk.finance.yahoo.com
InVivo Therapeutics Holdings Corp. (NVIV)
July 13, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
June 8, 2022 | finance.yahoo.com
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
See More Headlines
Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/14/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVIV
CUSIP
N/A
CIK
1292519
Web
www.invivotherapeutics.com
Phone
(617) 863-5500
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,490,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-75.04%
Return on Assets
-65.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.30
Quick Ratio
14.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.48 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
3,110,000
Free Float
3,085,000
Market Cap
$2.21 million
Optionable
Not Optionable
Beta
0.74
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Richard M. Toselli (Age 65)
    President, CEO, Chief Medical Officer & Director
    Comp: $825.2k
  • Mr. Richard C. Christopher (Age 53)
    CFO & Treasurer
    Comp: $537.82k
  • Ms. Heather M. Hamel J.D. (Age 33)
    Chief Legal Officer & General Counsel
    Comp: $446.96k
  • Dr. Robert S. Langer Jr. (Age 74)
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Joseph Philip Vacanti M.D. (Age 74)
    Co-Founder

Key Competitors

View All Competitors














NVIV Stock Analysis - Frequently Asked Questions

How have NVIV shares performed in 2023?

InVivo Therapeutics' stock was trading at $2.35 at the start of the year. Since then, NVIV shares have decreased by 69.8% and is now trading at $0.71.
View the best growth stocks for 2023 here.

Are investors shorting InVivo Therapeutics?

InVivo Therapeutics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,000 shares, a decline of 88.2% from the October 31st total of 8,500 shares. Based on an average daily volume of 12,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's shares are short sold.
View InVivo Therapeutics' Short Interest.

When is InVivo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NVIV earnings forecast.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.87) EPS for the quarter.

When did InVivo Therapeutics' stock split?

InVivo Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).

How do I buy shares of InVivo Therapeutics?

Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NVIV) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -